Prince Kumar Singh

Dr. Prince Kumar Singh

Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2022 in ACS Omega
Verified
Journal Article
Open access
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
JSJagreeti Singh
Jagreeti Singh
TMTapas Medhi
Tapas Medhi
AKAditya Kumar
Aditya Kumar
Diabetes is a group of metabolic disorders characterized by elevated blood sugar levels, leading to many undesirable health consequences. There are many herbal formulations, traditionally used by the Northeast Indian population for disease management. These formulations require scientific validations to optimize their efficacy and increase their popularity. In this study, we attempt to scientifically validate a polyherbal formulation traditionally used for the management of diabetes through preliminary phytochemicals investigation, characterization of potential phytochemicals using Fourier transform infrared (FT-IR) spectroscopy, high-resolution liquid chromatography mass spectrometry (HR-LC/MS) analysis, and in silico characterization of physiochemical, drug-likeness, and pharmacokinetic properties of identified phytochemical compounds. Qualitative phytochemical screening of various extracts of the formulation confirmed the presence of alkaloids, phenols and tannins, flavonoids, fats, and oils. Phytochemical quantification of the various extracts showed that the highest total phenolic content is present in the ethanolic extract (35.61 ± 0.15 mg GAE/g), while the highest total flavonoid content is present in the chloroform extract (76.33 ± 2.96 mg QE/g) of the formulation. FT-IR spectroscopic analysis revealed various characteristic band values with various functional groups in the formulation extract such as amines, alcohol, fluoro compounds, phenol, alkane, alkene, and conjugated acid groups. HR-LC/MS analyses identified nearly 51 compounds including 9 small peptides and 42 potential phytochemical compounds. In silico SwissADME analysis of identified compounds revealed 25 potential compounds following Lipinski's rule and showing drug-like characteristics, and out of them, 16 compounds exhibited good oral bioavailability, as revealed in the bioavailability radar. The overall study showed that the presented polyherbal formulation is enriched with bio-active phytochemical compounds with good pharmaceutical values.

28 November 2022 in Redox Biology
Verified
Journal Article
Open access
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
ASAseel Saadi
Aseel Saadi
YSYara Sheeni
Yara Sheeni
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Recent work by us and others has implicated NADPH oxidase (NOX) enzymes as main producers of reactive oxygen species (ROS) following a brain insult such as status epilepticus, contributing to neuronal damage and development of epilepsy. Although several NOX isoforms have been examined in the context of epilepsy, most attention has focused on NOX2. In this present study, we demonstrate the effect of gp91ds-tat, a specific competitive inhibitor of NOX2, in in vitro epileptiform activity model as well as in temporal lobe epilepsy (TLE) model in rats. We showed that in in vitro seizure model, gp91ds-tat modulated Ca2+ oscillation, prevented epileptiform activity-induced ROS generation, mitochondrial depolarization, and neuronal death. Administration of gp91ds-tat 1 h after kainic acid-induced status epilepticus significantly decreased the expression of NOX2, as well as the overall NOX activity in the cortex and the hippocampus. Finally, we showed that upon continuous intracerebroventricular administration to epileptic rats, gp91ds-tat significantly reduced the seizure frequency and the total number of seizures post-treatment compared to the scrambled peptide-treated animals.

8 May 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
SHWETA MAURYASHWETA MAURYA
SHWETA MAURYA
ASAseel Saadi
Aseel Saadi
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Oxidative stress is a pivotal driver of epileptogenesis and seizure-induced neuronal pathology, with NADPH oxidase 2 (NOX2) serving as a major source of reactive oxygen species (ROS) in the brain. Despite its established role in seizure pathophysiology, the therapeutic implications of selective NOX2 inhibition in epilepsy remain insufficiently explored. Here, we investigate the effect of GSK2795039, a potent NOX2 inhibitor, using both in vitro and in vivo epilepsy models. In vitro, mixed cortical neuroglial cultures were treated with 4-aminopyridine (4-AP) and picrotoxin (PTX) to induce epileptiform activity. Calcium imaging and dihydroethidium (DHE) fluorescence assays revealed that GSK2795039 significantly reduced synchronous Ca2+ oscillations and ROS accumulation. In vivo, adult rats implanted with ECoG transmitters were pretreated with GSK2795039 prior to pentylenetetrazol (PTZ) administration to evoke seizures. ECoG recording and behavioral seizure scoring showed that GSK2795039 pretreatment inhibited the seizure severity, duration and cumulative seizure burden. Molecular analyses, including quantitative PCR and western blotting, revealed a significant downregulation of NOX2 mRNA in both the hippocampus and cortex, although protein levels remained unchanged. Additionally, immunofluorescence and histological staining confirmed that GSK2795039 mitigated oxidative DNA damage, preserved hippocampal neuronal integrity, and differentially modulated pro- and anti-inflammatory cytokine expression. These findings underscore NOX2 inhibition as a compelling neuroprotective strategy and highlight the potential of GSK2795039 to suppress oxidative and inflammatory cascades in epilepsy. Targeting NOX2 may represent a promising avenue for precision therapeutics in oxidative stress-driven epilepsy.

8 November 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SSSereen Sandouka
Sereen Sandouka
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
ASAseel Saadi
Aseel Saadi
RTRhoda Olowe Taiwo
Rhoda Olowe Taiwo
YSYara Sheeni
Yara Sheeni
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Background: Epilepsy affects over 65 million people worldwide and significantly burdens patients, caregivers, and society. Drug-resistant epilepsy occurs in approximately 30% of patients and growing evidence indicates that oxidative stress contributes to the development of such epilepsies. Activation of the Nrf2 pathway, which is involved in cellular defense, offers a potential strategy for reducing oxidative stress and epilepsy treatment. Dimethyl fumarate (DMF), an Nrf2 activator, exhibits antioxidant and anti-inflammatory effects and is used to treat multiple sclerosis. Methods: The expression of Nrf2 and its related genes in vehicle or DMF treated rats were determined via RT-PCR and Western blot analysis. Neuronal cell death was evaluated by immunohistochemical staining. The effects of DMF in preventing the onset of epilepsy and modifying the disease were investigated in the kainic acid-induced status epilepticus model of temporal lobe epilepsy in rats. The open field, elevated plus maze and T-Maze spontaneous alteration tests were used for behavioral assessments. Results: We demonstrate that administration of DMF following status epilepticus increased Nrf2 activity, attenuated status epilepticus-induced neuronal cell death, and decreased seizure frequency and the total number of seizures compared to vehicle-treated animals. Moreover, DMF treatment reversed epilepsy-induced behavioral deficits in the treated rats. Moreover, DMF treatment even when initiated well after the diagnosis of epilepsy, reduced symptomatic seizures long after the drug was eliminated from the body. Conclusions: Taken together, these findings suggest that DMF, through the activation of Nrf2, has the potential to serve as a therapeutic target for preventing epileptogenesis and modifying epilepsy.

4 January 2023 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
SSSereen Sandouka
Sereen Sandouka
ASAseel Saadi
Aseel Saadi
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
RORhoda Olowe
Rhoda Olowe
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Background: Drug resistance is a particular problem in patients with temporal lobe epilepsy, where seizures originate mainly from the hippocampus. Many of these epilepsies are acquired conditions following an insult to the brain such as a prolonged seizure. Such conditions are characterized by pathophysiological mechanisms including massive oxidative stress that synergistically mediate the secondary brain damage, contributing to the development of epilepsy. The transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) has emerged in recent years as an attractive therapeutic approach targeting to upregulate the antioxidative defenses in the cell, to ameliorate the oxidative stress-induced damage. Thus, it is important to understand the characteristics of Nrf2 activation during epileptogenesis and epilepsy. Here, we studied the temporal, regional, and cell-type specific expression of Nrf2 in the brain, in a rat model of temporal lobe epilepsy. Results: Early after status-epilepticus, Nrf2 is mainly activated in the hippocampus and maintained during the whole period of epileptogenesis. Only transient expression of Nrf2 was observed in the cortex. Nevertheless, the expression of several Nrf2 antioxidant target genes was increased within 24 h after status-epilepticus in both the cortex and the hippocampus. We demonstrated that after status-epilepticus in rats, Nrf2 is predominantly expressed in neurons in the CA1 and CA3 regions of the hippocampus, and only astrocytes in the CA1 increase their Nrf2 expression. Conclusions: In conclusion, our data identify previously unrecognized spatial and cell-type dependent activation of Nrf2 during epilepsy development, highlighting the need for a time-controlled, and cell-type specific activation of the Nrf2 pathway for mediating anti-oxidant response after brain insult, to modify the development of epilepsy.

11 August 2022 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
ASAseel Saadi
Aseel Saadi
SSSereen Sandouka
Sereen Sandouka
EGEtty Grad
Etty Grad
Prince Kumar SinghPrince Kumar Singh
Prince Kumar Singh
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
The NADPH Oxidase (NOX) enzymes are key producers of reactive oxygen species (ROS) and consist of seven different isoforms, distributed across the tissues and cell types. The increasing level of ROS induces oxidative stress playing a crucial role in neuronal death and the development of epilepsy. Recently, NOX2 was reported as a primary source of ROS production, activated by NMDA receptor, a crucial marker of epilepsy development. Here, we demonstrate spatial, temporal, and cellular expression of NOX2 and NOX4 complexes in in-vitro and in-vivo seizure models. We showed that the expression of NOX2 and NOX4 was increased in the initial 24 h following a brief seizure induced by pentylenetetrazol. Interestingly, while this elevated level returns to baseline 48 h following seizure in the cortex, in the hippocampus these levels remain elevated up to one week following the seizure. Moreover, we showed that 1- and 2- weeks following status epilepticus (SE), expression of NOX2 and NOX4 remains significantly elevated both in the cortex and the hippocampus. Furthermore, in in-vitro seizure model, NOX2 and NOX4 isoforms were overexpressed in neurons and astrocytes following seizures. These results suggest that NOX2 and NOX4 in the brain have a transient response to seizures, and these responses temporally vary depending on, seizure duration, brain region (cortex or hippocampus), and cell types.